title: Fish oil supplementation reduces beta-very low density lipoprotein in type III dysbetalipoproteinemia.
abstract: beta-Very low density lipoproteins (beta-VLDLs) are atherogenic, cholesterol-rich chylomicron and VLDL remnants that accumulate in the plasma of type III dysbetalipoproteinemic subjects. To evaluate the effect of fish oil supplementation on plasma beta-VLDL concentrations, we compared the lipid and lipoprotein responses in nine type III and nine type IV hyperlipidemic subjects. Each individual received 6 g/day omega-3 fatty acids for 12 weeks. Before treatment, the mean total cholesterol, total triglyceride, VLDL triglyceride, low density lipoprotein (LDL) cholesterol, and high density lipoprotein (HDL) cholesterol levels were not different between groups. Conversely, VLDL cholesterol, intermediate density lipoprotein (IDL) cholesterol, and IDL triglycerides were higher in type III than in type IV subjects. Fish oil supplementation was associated with significantly lower levels of cholesterol (-50%), triglycerides (-50%), and apolipoprotein B (-50%) in the d less than 1.006 g/ml ultracentrifugation plasma fraction in both groups, compatible with a reduction in VLDL in type III and type IV subjects, and in beta-VLDL in type III subjects. This finding was confirmed by analysis of the plasma zonal ultracentrifugation profile and the agarose gel electrophoretic pattern of lipoproteins, which showed a reduction in but not a disappearance of remnant particles, suggesting that not all beta-VLDL had been cleared after treatment. The levels of IDL cholesterol and IDL triglycerides (1.006 less than d less than 1.019 g/ml) were not affected in either group. Initially low LDL cholesterol (1.019 less than d less than 1.063 g/ml) and HDL cholesterol levels rose significantly in both groups. In type III hyperlipidemics, all LDL cholesterol values remained below 120 mg/dl, whereas they were higher than 150 mg/dl after treatment in two individuals with type IV hyperlipidemia.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, Canada.
authors.forename: J
authors.initials: J
authors.lastname: Dallongeville
authors.forename: L
authors.initials: L
authors.lastname: Boulet
authors.forename: J
authors.initials: J
authors.lastname: Davignon
authors.forename: S
authors.initials: S
authors.lastname: Lussier-Cacan
mesh_terms: D000328:Adult; D000368:Aged; D001053:Apolipoproteins / Q000097:blood; D002501:Centrifugation, Zonal; D002784:Cholesterol / Q000097:blood; D002914:Chylomicrons / Q000097:blood; D004587:Electrophoresis, Agar Gel; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006952:Hyperlipoproteinemia Type III / Q000097:blood*; D006953:Hyperlipoproteinemia Type IV / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D013223:Statistics as Topic; D014280:Triglycerides / Q000097:blood
chemical_list: D001053:Apolipoproteins; D002914:Chylomicrons; D015525:Fatty Acids, Omega-3; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D002784:Cholesterol